Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
about
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulationTherapeutic and clinical aspects of portal vein thrombosis in patients with cirrhosisImplications of apixaban for dental treatmentsDiagnosis and Management of Acute Intracerebral Hemorrhage.Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures.Management of anticoagulant-related intracranial hemorrhage: an evidence-based review.Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants.Management of acute stroke in patients taking novel oral anticoagulants.Drug adherence in patients taking oral anticoagulation therapy.Emergency reversal of anticoagulation: novel agents.Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat?Pharmacology and mechanisms of action of new oral anticoagulants.Monitoring of hematological and hemostatic parameters in neurocritical care patients.Management of hemorrhage with the target-specific oral anticoagulants.Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence.Monitoring and reversal strategies for new oral anticoagulants.Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience.Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.The discovery of dabigatran etexilate for the treatment of venous thrombosis.Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?Use of rivaroxaban in patients with stroke.New Oral Anticoagulants and Their Reversal Agents.Medical management of intracerebral haemorrhage.Rationale and design of the ODIn-AF Trial: randomized evaluation of the prevention of silent cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation.Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation.Comparison of different laboratory tests in the evaluation of hemorrhagic risk of patients using rivaroxaban in the critical care setting: diagnostic accuracy study.Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre.Accidental Thrombolysis in a Stroke Patient Receiving Apixaban.Intravenous thrombolysis in a stroke patient receiving rivaroxaban.Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice.Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke.Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in.Intravenous thrombolysis in stroke patients receiving rivaroxaban.Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke.Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol.Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians.Measurement of dabigatran: previously demonstrated Hemoclot(®) Thrombin Inhibitor assay reagent instability on Sysmex CS-2100i is no longer an issue.[Monitoring of NOAC].[Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?]
P2860
Q26749141-A0CAE640-C7F3-47E2-8C88-2085329850A8Q26774531-959DEBC1-7977-4A2C-A4B4-F6AF78187B62Q28079697-5BBD40AE-6FCB-49F0-800C-1CDCCD9544DCQ31136660-EDC671CA-ACA2-4BC7-8238-854B1565ECBAQ33656869-62E8D011-49BF-4644-AF02-4FA563D0760DQ33750215-6BF33A34-7BD7-4140-932A-1D95BD111E56Q33875897-3CFA5B69-501C-4C01-A5DE-9E4318880B30Q34111320-EC23C812-05C4-47C6-B5FF-CE6868FF8A75Q38133767-483213CF-3B1D-45E6-9A7B-A89454AC9BE0Q38223609-1D9CB7E9-BC9E-4F8C-ADC9-CAC24C76A9AFQ38228428-5365F301-C3B9-4CF7-8891-E2A277BDCAF7Q38246726-5B199B5A-3F3D-4919-81BF-80440570DFA2Q38248152-C93C19CD-C308-49DA-A332-E84571AB1992Q38254250-939E3413-4435-412E-94DA-36E459C86BF4Q38255703-ECE00838-BBC3-40F9-BD24-7447C0BE096BQ38272325-D00EB9FD-A962-4535-8C4D-A190D9DD087EQ38312159-0FB00FAF-F198-41C4-85F3-4AA51FCD26BAQ38380827-5661C387-234C-4F4F-AC50-ACCECC50B050Q38723869-ECA1BCAA-0F90-45C5-9ACA-7A6EB7446DDDQ38829586-4CFE2591-D373-43A7-B28D-E63B2182710FQ38895665-E2D2A649-6268-48F6-AA99-EA6BF7985398Q38941684-9DD88742-9C71-4318-9175-7D2DA4223983Q38970532-BEBFB5F6-FCAC-49FC-A599-5A9FE95D46BFQ39010418-1AB2E95E-53E6-4F57-ACAA-0F4B9BEA0E8FQ40378922-802D02E9-F916-4517-BD12-084B95C55938Q41307231-E5C2332B-AB5F-41D4-91A6-E0E49E76D5C4Q41413847-E4EF8D62-8B5F-4A19-9478-02D0D0B5FD3FQ41564940-715132AC-B77D-4F09-B10D-4AA311CA2D5BQ41949411-04B25DF3-D9C0-4DB2-B7A2-72C375A76520Q42258033-4A19F740-7277-4DF0-AB24-0D769FAA5188Q42380272-2D1671F5-A924-437B-9D53-623318D1E382Q42415890-0BF6ED31-C0F4-4606-B263-72D7A3A0AD8EQ42822669-5BB58FC2-F75F-4020-BE06-A30442028B04Q44285413-4BCEE521-D6DE-4AE7-ABC7-B4B303F06B3AQ47989628-D76C1114-C8A6-4C52-AD70-2A1102F4F0F3Q48163723-F61A40CA-FDB2-4DD4-B651-B3D9C3285F0CQ48199813-08824079-D36A-462F-BFF2-94BBD1292C33Q48298472-3E26F421-9A45-412D-9262-2C832644DB6CQ50955231-ECE1ED84-E919-410D-B91B-43AEF8FA0955Q51771619-365E9D37-8261-4418-A267-52380E74FAD7
P2860
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Recommendations for the emerge ...... n, dabigatran and rivaroxaban.
@en
type
label
Recommendations for the emerge ...... n, dabigatran and rivaroxaban.
@en
prefLabel
Recommendations for the emerge ...... n, dabigatran and rivaroxaban.
@en
P2093
P2860
P1476
Recommendations for the emerge ...... n, dabigatran and rivaroxaban.
@en
P2093
G Nickenig
H-C Diener
M Dichgans
P2860
P2888
P304
P356
10.1007/S00392-013-0560-7
P577
2013-05-14T00:00:00Z